For decades, the KRAS gene was a locked door. Pancreatic cancer, driven by its mutations in more than 90% of cases, killed quickly. Chemotherapy bought months, not years. No drug could grab hold of the protein’s smooth surface. That changed.
Daraxonrasib works by a different mechanism. It does not try to bind KRAS directly. Instead, it grabs a helper molecule inside cells called cyclophilin A. The two together form a clamp that locks onto active, mutated KRAS and shuts off its growth signal. This is not a targeted therapy in the old sense. It is a broader trap, one that catches multiple RAS mutations at once. That breadth matters. Cancer cells evolve resistance by mutating further. A drug that hits several versions of the target at the same time makes escape harder.
The numbers from the Phase 3 trial, published in the New England Journal of Medicine, are stark. Five hundred patients with metastatic pancreatic cancer who had already failed prior treatment were given either daraxonrasib or standard chemotherapy. Those on the pill lived a median of 13.2 months. Those on chemo lived 6.7 months. That is a 60% reduction in the risk of death. Nearly double the survival time. In a disease where a few extra weeks was once a win, this is a different category.
Side effects exist. Most patients developed a skin rash. Mouth sores, diarrhea, and nausea were common. But patients on daraxonrasib were less likely to stop treatment than those on chemotherapy. They also reported better quality of life. That is not a minor footnote. Chemotherapy for pancreatic cancer is brutal. Patients often choose shorter survival over its toxicity. A drug that keeps them feeling well enough to stay on it matters as much as the months it adds.
Revolution Medicines developed the drug. The company has released the full trial data. Regulatory approval is still pending. That is the next hurdle. The FDA will review the evidence. If approved, daraxonrasib would become the first oral drug targeting KRAS-driven pancreatic cancer to reach the clinic. It would not be a cure. Patients still die. But 13 months versus 6.7 months is a shift in the landscape.
Experts quoted in the report describe daraxonrasib as potentially the most significant advance in pancreatic cancer treatment in a generation. That is not hyperbole. The last major step forward was the FOLFIRINOX chemotherapy regimen, approved more than a decade ago. Since then, progress has been incremental at best. This drug breaks a long drought.
The mechanism matters beyond pancreatic cancer. KRAS mutations drive lung cancer, colorectal cancer, and others. If daraxonrasib works broadly across RAS-driven tumors, its impact could extend far beyond the pancreas. The trial published so far is limited to one disease, one setting. But the underlying biology suggests wider applications. That will be the next wave of studies.
For now, the data is clear. A pill that grabs cyclophilin A, clamps onto KRAS, and shuts it down has nearly doubled survival in the deadliest of cancers. The door is no longer locked.
